Lantheus Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNTH research report →
Range $102.5 – $109
Price Chart
About the company
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses.
- CEO
- Mary Anne Heino
- IPO
- 2015
- Employees
- 1,193
- HQ
- Bedford, MA, US
Get TickerSpark's AI analysis on LNTH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.68B
- P/E
- 24.66
- Fwd P/E
- 18.37
- PEG
- 0.36
- P/S
- 4.27
- P/B
- 4.92
- EV/EBITDA
- 13.35
- Div Yield
- 0.00%
- Gross Margin
- 61.26%
- Op Margin
- 18.62%
- Net Margin
- 17.28%
- ROE
- 21.72%
- ROIC
- 10.87%
Latest fiscal year · YoY change
- Revenue
- $1.54B+0.5%
- Gross Profit
- $941.95M-4.7%
- Op Income
- $310.83M
- Net Income
- $233.56M-25.2%
- EPS
- $3.46-23.5%
- OCF Growth
- -28.4%
- FCF Growth
- -28.2%
- 52W High
- $111.86
- 52W Low
- $54.94
- 50D MA
- $100.46
- 200D MA
- $94.00
- Beta
- -0.06
- RSI (14)
- 69
- Avg Volume
- 1.02M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lantheus said it had a strong first quarter, reaffirmed 2026 guidance, and highlighted key regulatory wins for PYLARIFY TRUVU and PNT2003 as it positions for growth acceleration in 2027.· May 7, 2026
- Q1 revenue was $377.3 million, up 1.2% year over year, and adjusted EPS was $1.46.
- Gross margin was 67.0%, flat with last year, helped by the spec divestiture and product volumes but pressured by PYLARIFY net price and new manufacturing costs.
- PYLARIFY volume rose about 5.8% year over year, while NEURACEQ revenue was $35.4 million and DEFINITY revenue was $84.6 million.
- Management reaffirmed full-year 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted EPS of $5 to $5.25.
- The company emphasized 2026 as a year of execution and regulatory milestones, with PYLARIFY TRUVU launch prep, Actinium launch readiness, and PNT2003 tentative approval.
- Management repeatedly framed 2027 as the year when the benefits of these efforts should start to show more clearly.
First-quarter revenue was $377.3 million, up 1.2% year over year, and up 8.6% excluding $25.2 million of prior-year spec revenue that was divested. GAAP diluted EPS was $1.80 and adjusted EPS was $1.46, down 4.6% from the prior year period; reported net income was $118.4 million and adjusted profit was $95.8 million, down 12.5%. Gross profit margin was 67.0%, flat year over year. By segment, oncology revenue (PYLARIFY) was $240.9 million, down 6.5%; neurology revenue (NEURACEQ) was $35.4 million; cardiology revenue (DEFINITY) was $84.6 million, up 6.8%; and strategic partnerships and other revenue was $16.3 million, up 52.1%. Operating cash flow was $125.1 million, free cash flow was $121.9 million, and cash and cash equivalents net of restricted cash were $498.6 million at quarter-end. For 2026, the company reiterated revenue guidance of $1.4 billion to $1.45 billion and adjusted EPS guidance of $5 to $5.25.
Mary Heino described the quarter as a strong start and repeatedly stressed that 2026 is a year of commercial execution and regulatory progress, with growth acceleration expected to begin in 2027. Her strategic focus was on protecting the PSMA PET franchise, executing a seamless transition from PYLARIFY to PYLARIFY TRUVU, building NEURACEQ through deeper account penetration and expanded manufacturing footprint, and advancing late-stage pipeline assets. Her tone was confident and disciplined, but also cautious about timing launches and capital deployment.
Bob Marshall said the quarter came in solidly across the portfolio, with revenue up 1.2% year over year and gross margin at 67.0%, which he said is likely to trend toward the high end of the earlier 65% to 66% range. He pointed to the main margin drivers as the spec divestiture, PYLARIFY and DEFINITY volumes, and DEFINITY price, partly offset by lower PYLARIFY net price, Evergreen inclusion, and NEURACEQ ramp-related dilution. He also highlighted cash generation of $125.1 million in operating cash flow, $121.9 million in free cash flow, $498.6 million in cash and equivalents, $200 million remaining on buybacks, and access to a $750 million undrawn revolver. On guidance, he said the company still expects full-year 2026 revenue of $1.4 billion to $1.45 billion and EPS of $5 to $5.25, while keeping an eye on competitive dynamics and cost discipline.
Analysts focused heavily on whether the company’s full-year guidance implied a step-down after a strong Q1, and management said it was being prudent rather than signaling a deterioration. They cited ongoing competitive monitoring, the timing of pass-through changes, and the upcoming CEO transition as reasons to hold guidance steady. Questions on TRUVU centered on contracting, customer readiness, pricing, and the switch from PYLARIFY; management said conversions will be site-by-site, begin in Q4, and only occur once coding, coverage, and reimbursement systems are ready. On PNT2003, management explained that tentative approval means the FDA review is substantively complete, but final approval still depends on Hatch-Waxman timing and related legal proceedings, and Bob Marshall said it is not embedded in 2026 guidance.
The quarter showed stable underlying demand, with PYLARIFY volume growth, NEURACEQ revenue growth, and DEFINITY growth all contributing. Management also has multiple near-term catalysts: TRUVU approval and launch preparation, Actinium’s extended review, and PNT2003 tentative approval, while cash flow remained strong and the balance sheet stayed flexible.
Management repeatedly acknowledged competitive pressure in PSMA PET and said it is remaining prudent until later in the year. TRUVU’s financial benefit will not begin until 2027, and both Actinium and PNT2003 still face timing, reimbursement, and legal hurdles before they can become meaningful contributors. PYLARIFY revenue was down year over year, and management said the company is still watching for competitors gaining footing and for pass-through changes later in the year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.4%
- Shares Outstanding
- 65.40M
- Float Shares
- 60.43M
of shares held by institutions
483 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for LNTH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Oct 15, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 14, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 13, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 7, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 28, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.66M | ▲ 259.72K |
| Vanguard Group Inc | 6.70M | ▼ 253.04K |
| Jupiter Topco LLC | 5.19M | ▲ 5.19M |
| Pentwater Capital Management LP | 3.90M | ▲ 3.90M |
| American Century Companies Inc | 3.20M | ▲ 386.83K |
| Vanguard Portfolio Management LLC | 3.13M | ▼ 108.76K |
| Farallon Capital Management, L.L.C. | 3.11M | ▼ 2.47M |
| Vanguard Capital Management LLC | 2.92M | ▼ 12.03K |
| Janus Henderson Group Ltd. | 2.77M | ▲ 2.77M |
| State Street Corp | 2.49M | ▼ 8.90K |
| Lmr Partners Llp | 2.11M | ▲ 2.11M |
| Geode Capital Management, LLC | 2.02M | ▲ 182.93K |
Held by 457 ETFs
Biggest fund positions in LNTH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Heino Mary Anne | other | 6,206 |
| Aug 31, 26 | Marshall Robert J. Jr. | other | 721 |
| Aug 17, 26 | Dinkelborg Ludger | other | 2,536 |
| Aug 17, 26 | Brown Kimberly | other | 463 |
| May 14, 26 | McHugh Julie | other | 4,137 |
| May 14, 26 | Morrow Phuong Khanh | other | 4,137 |
| May 14, 26 | Maeusli Heinz Christoph | other | 4,137 |
| May 14, 26 | LENO SAM R | other | 4,137 |
| May 14, 26 | Pruden Gary J | other | 4,137 |
| May 14, 26 | Baylor-Henry Minnie | other | 4,137 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LNTH coverage
Recent articles, reports, and earnings notes.
No research on LNTH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LNTH report →Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer's Disease
globenewswire.com · Nov 16
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
prnewswire.com · Nov 9
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
globenewswire.com · Nov 5
Lantheus Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting
globenewswire.com · Nov 2
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
globenewswire.com · Oct 6
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Rated “Hold” by Wall Street Analysts
defenseworld.net · Oct 1
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
globenewswire.com · Sep 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.